Medicus Pharma reports positive dose response in skin cancer trial

May 6, 2026 7:30 AM

Medicus Pharma Ltd. (NASDAQ: MDCX) announced results from an expanded analysis of its Phase 2 SKNJCT-003 study evaluating a doxorubicin ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found